Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251323 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12904497 | 0.76 | SIGMAR1 (0.42) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12904644 | 0.76 | SIGMAR1 (0.42) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL20670512 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10153397 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10153401 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12905011 | 0.74 | MAPT (0.41) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12904929 | 0.74 | MAPT (0.38) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12309 | 0.73 | — | — | |
| SCHEMBL12888984 | 0.73 | MAPT (0.40) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SMN1; SMN2 833/4885MAPT 1769/4885CYP2C9 3614/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885MAPT 4169/4885CYP2C9 4867/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885MAPT 4169/4885CYP2C9 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.